GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2021. In our inaugural year for these awards, we wanted to bring forth and recognize not only the most experienced and talented investors in healthcare but also those that help advance innovation across the sector. Over 750 investors were considered. Whether in healthcare software, healthcare services, medical technologies, biotechnology, the connected patient experience, or other areas, the accomplished individuals who were ultimately selected have demonstrated a deep commitment to healthcare and as a result have succeeded both from a business standpoint as well as in having significant societal impact.
This year’s awardees were nominated by their firms, portfolio companies, healthcare industry colleagues, and/or peers at other investment firms. Awardee selections and rankings were based on deal experience and track record, strategic and operational capabilities provided to portfolio companies, unique and differentiated attributes, as well as contributions to charitable work and overall industry advancement. Healthcare plays a crucial role in the quality of our lives, underpins all other business and economic activity, and ultimately determines the state of our world. Please join us in recognizing and celebrating the achievements of The Top 25 Healthcare Investors of 2021.
Firm: TPG Capital
Title: Co-Managing Partner
Todd Sisitsky is the Co-Managing Partner of TPG Capital, the firm’s dedicated private equity platform, and serves as a member of TPG’s Executive Committee. Todd also co-leads TPG Capital’s industry-leading healthcare franchise, where he and his partners oversee investments across all segments of the sector including healthcare services, pharmaceutical products and services, and medical devices and technologies. Over the past 20 years, under Todd and his partners’ leadership, TPG Capital’s healthcare team has deployed more than $21 billion in capital, including co-investments, across more than 25 companies. In 2019, they launched TPG Healthcare Partners, a first-time, sector-dedicated vehicle that is recognized in the industry as one of the largest pools of capital dedicated to healthcare investments.
During his tenure at the firm, Todd has led some of TPG’s most notable healthcare investments, including Allogene, Adare Pharmaceuticals, Aptalis, Biomet, Convey Health Solutions, Exactech, Fenwal, IMS Health/IQVIA, Par Pharmaceutical, and Surgical Care Affiliates, among others. Todd received an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude. Todd currently serves as the chair of the Dartmouth Medical School’s board of advisors, and as a member of the board of directors of Grassroot Soccer.
Firm: General Atlantic
Title: Managing Director, Global Head of Healthcare
Robb Vorhoff is a Managing Director and Global Head of General Atlantic’s Healthcare sector, and also serves on the firm’s Management Committee. He joined General Atlantic in 2003. Robb currently sits on the boards of Alignment Healthcare, Alternate Solutions Health Network, Doctor on Demand, Equality Health, Landmark Health, Marathon Health, Oak Street Health, OneOncology, Vida Health, and the Healthcare Private Equity Association (HCPEA). Robb is involved with several nonprofits supporting entrepreneurship, including as a board member for both The Idea Village, an organization focused on regional startups in his hometown of New Orleans, as well as Echoing Green, an incubator for social impact-focused businesses. Prior to joining General Atlantic, Robb was an analyst at Greenhill & Co. He graduated with a B.S. in Finance from the McIntire School of Commerce at the University of Virginia.
“For over 40 years, General Atlantic has been a global growth equity investor that partners with visionary business leaders during the most challenging phases of their careers to help de-risk their companies’ growth. I couldn’t be prouder of the global network of healthcare entrepreneurs we partner with for their dedication, particularly amid a widespread pandemic this past year, and for the important work they are doing to drive access and innovation in healthcare.”
Firm: Blackstone Growth
Title: Senior Managing Director, Global Head of Healthcare
Ram Jagannath is a Senior Managing Director and Global Head of Healthcare for Blackstone Growth and Tactical Opportunities, based in New York. He is a member of the Blackstone Growth Investment Committee. Since joining Blackstone in 2019, Mr. Jagannath has led Blackstone’s investments in HealthEdge, Burgess Group, Bright Health, Cryoport (NASDAQ: CYRX), ZO Skin Health, Altruista Health, Ginger and Hydrogen Health, and was involved in Blackstone’s investments in Alnylam/inclisiran royalty (NASDAQ: ALNY) and Precision Medicine Group. Before joining Blackstone, Mr. Jagannath was a founding Partner of Navab Capital Partners (NCP), where he was Head of Healthcare and a member of NCP’s Management and Investment Committees. Prior to NCP, he was a Managing Director of The Carlyle Group, focused on healthcare investments in Carlyle’s flagship US Buyout private equity fund. During his twelve years at Carlyle, Mr. Jagannath was a member of the teams which invested in One Medical Group (NASDAQ: ONEM), Pharmaceutical Product Development (NASDAQ: PPD), X-Chem (GHO Capital), Ortho Clinical Diagnostics (NASDAQ: OCDX), Healthscope Ltd. (ASX: HSO), and HCR ManorCare (NYSE: HCP/ProMedica). Previously, he worked at Genstar Capital and Thomas Weisel Capital Partners.
Mr. Jagannath currently serves on the Board of Directors of HealthEdge, Cryoport, ZO Skin Health, Ginger and Hydrogen Health. He also serves on the Board of Visitors of the Duke University Pratt School of Engineering and on the Kellogg School of Management Private Equity Advisory Council, as well as on the Board of Directors of Centering Healthcare Institute. Mr. Jagannath was previously a term member of the Council on Foreign Relations. Mr. Jagannath received a B.S.E. in Biomedical and Electrical Engineering with a minor in Economics from Duke University, a J.D. from the Northwestern University Pritzker School of Law, and an M.B.A. from the Northwestern University Kellogg School of Management. After Duke, he was a Fulbright Scholar in Economic Development at the University of Zagreb in Croatia.
Firm: Thomas H. Lee Partners
Title: Managing Director, Head of Healthcare Vertical
Joshua M. Nelson is a Managing Director at Thomas H. Lee Partners. Prior to joining Thomas H. Lee Partners, Mr. Nelson worked at JPMorgan Partners, the private equity affiliate of JPMorgan Chase. Mr. Nelson also worked at McKinsey & Co. and The Beacon Group, LLC.
Mr. Nelson is currently a director of Adare Pharma Solutions, Agiliti Health, Inc., Autism Home Care Holdings, Inc., CSafe Global, Hospice Care, Professional Physical Therapy (ProPT), Senior Home Care Holdings, Inc. and Syneos Health (formerly inVentiv Health, Inc.). His prior directorships include 1-800 CONTACTS, Inc., Curo Health Services, Hawkeye Energy Holdings, Healthcare Staffing Services, Intermedix Corporation and Party City. Mr. Nelson holds an A.B., summa cum laude, in Politics from Princeton University and an M.B.A. with Honors from Harvard Business School.
Firm: Silversmith Capital Partners
Title: Co-Founder and Managing Partner
Jeff co-founded Silversmith Capital Partners in 2015. In his role as a Managing Partner, Jeff focuses on investments in Healthcare IT & Services. Within Healthcare IT, Jeff partners with talented leaders of proven, high growth software and data companies that can either materially improve clinical outcomes or reduce administrative inefficiency within all segments of the U.S. healthcare ecosystem. Jeff’s healthcare services investments are centered around innovative care delivery models oriented towards value-based care that can be scaled both organically and through M&A. Jeff has led many of the firm’s healthcare investments including Iodine Health, LifeStance Health, MediQuant, Nordic, Panalgo, Partners Surgical, Sound Physicians, Upperline Health and Within3. Some of Jeff’s notable investments prior to co-founding Silversmith included ABILITY Network, Liberty Dialysis, Liazon and MedHOK.
Jeff received an AB in Government and Mathematics from Dartmouth College where he graduated magna cum laude and an M.B.A. with Distinction from Harvard Business School.
Firm: Silversmith Capital Partners
Title: Co-Founder and Managing Partner
Jim co-founded Silversmith Capital Partners in 2015. In his role as Managing Partner, Jim focuses on investments across the firm’s two core verticals: SaaS & Information Services and Healthcare IT & Services. At Silversmith, he serves on the board of Centauri Health Solutions, Market Access Transformation, and Net Health. Prior to co-founding Silversmith, Jim served on the board of Passport Health (acquired by Experian) and MedHOK (acquired by Hearst). Over his career, he has served on the board of 20+ companies.
Jim received an A.B. in English & American Literature from Harvard College where he graduated magna cum laude.
Firm: Deerfield Management
Julian Harris, M.D., is an investment partner on the healthcare services and technology team at Deerfield. Since joining the firm in 2019, Dr. Harris has used his vast expertise to provide research and analysis on individual companies operating in the healthcare industry. In addition, Dr. Harris is the Chairman and Chief Executive Officer of ConcertoCare (concertocare.com), one of the nation’s leading tech-enabled companies focused on providing integrated care for seniors in the home. Dr. Harris has worked with a variety of healthcare services and technology organizations (private and public) that are both current and potential investment partners. Previously, Dr. Harris was the founding president of CareAllies, was an adviser to the Google Ventures (GV) team focused on healthcare services, and led the healthcare team in the White House Office—where he oversaw a $1 trillion budget and provided management and policy oversight for a range of national medical programs. He also served as the chief executive of the $11 billion Massachusetts Medicaid program.
Dr. Harris received his Bachelor of Arts degree in health policy and medical ethics from Duke University, graduating summa cum laude. Later, as a Rhodes Scholar, he earned a Master of Science degree from Oxford University. He would go on to train in internal medicine and primary care at Harvard Medical School’s Brigham & Women’s Hospital. Additionally, he is a graduate of the Wharton School of Business and the University of Pennsylvania’s School of Medicine, where he currently serves as an Adjunct Associate Professor. On top of his commercial duties, Dr. Harris is a trustee of the New York Academy of Medicine and a member of the advisory boards for the Leonard Davis Institute for Health Economics at Penn and the NYU Department of Population Health.
Firm: Great Hill Partners
Title: Managing Partner
Mark Taber, Managing Partner at Great Hill Partners, is responsible for transaction origination, investment policy, fundraising, investor relations and the general management of Great Hill Partners. Mark also leads the healthcare team and is currently a member of the Board of Directors of ParetoHealth, PartsSource, Quantum Health, RxBenefits and Vatica Health. He previously served on the Boards of numerous other companies, including healthcare companies such as FirstCall HealthCare, Passport Health Communications, Qualifacts and SterilMed. He is also a member of the Board of Trustees for Boston Medical Center’s Healthnet/Well Sense Health Plan and a member of the Finance Committee at Boston Medical Center.
Mark graduated from the J.L. Kellogg Graduate School of Management where he was an F.C. Austin Scholar and the Jim Packard Memorial Scholar. He also holds a B.A. in public policy studies from Duke University.
Firm: Great Hill Partners
Rafael Cofiño is a Partner at Great Hill Partners and joined the firm in 2012. His focus at the firm is on high growth healthcare and technology-enabled investment opportunities. Rafael currently serves on the board of directors for several leading healthcare companies, including ParetoHealth, PartsSource, Quantum Health, RxBenefits and Vatica Health. He formerly served on the Boards of Qualifacts (acquired by Warburg Pincus) and DealerRater (acquired by Cars.com) and was also involved in the investments of Passport Health Communications (acquired by Experian) and Wayfair (NYSE: W). Prior to joining Great Hill, Rafael held positions at Battery Ventures, Technology Crossover Ventures, Goldman Sachs and RBC Capital Markets.
Rafael earned a degree in finance from The University of Texas at Austin and an M.B.A. from Harvard Business School.
Firm: Johnson & Johnson Innovation
Title: Head of Innovation, East North America
Michal Preminger is the Head of Johnson & Johnson Innovation, East North America. In this role, she leads the Innovation Center team to build, advance, and manage the external R&D portfolio of co-investments spanning across pharmaceutical, consumer health, and medical devices. Her previous experience includes serving as the executive director of Harvard Medical School’s (HMS) Office of Technology Development, where she was responsible for development and commercialization of technologies emerging from research at HMS laboratories and for the strategy and execution of all industry collaborations.
Preminger has also held a number of business development and technology development positions at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company’s emerging drug discovery pipeline. Currently, she serves on the Scientific Advisory Board’s FutuRx Accelerator, and was, until recently, a member of the SAB of Prize4Life; and a Member of the Board of Directors of a number of companies, including Compugen and Alma Lasers. Preminger holds a Bachelor of Arts degree in medicine from Hadassah Medical School, Hebrew University, Jerusalem. She also received her M.B.A. degree from INSEAD and her Ph.D. degree in biological sciences from the Weizmann Institute of Science.
Firm: Frazier Healthcare Partners
Title: Managing Partner
Nader Naini joined Frazier Healthcare Partners in 1991 and has spent the past three decades serving on the firm’s management team, leading its Growth Buyout practice since 1995. Under Naini’s leadership, the private equity and venture capital firm has successfully raised more than $4 billion of limited partner capital and has realized more than $4.2 billion in exits. Milestones during his 30-year tenure with the firm include investments in such organizations as Aspen Education Group, CHG Healthcare, Priority Solutions International, Bravo Health, Laboratory Supply Company, and DSI Renal.
Prior to joining Frazier, Naini worked at Goldman Sachs & Co. in New York. He received his M.B.A. degree from the Leonard N. Stern School of Business at New York University and a B.A. degree in molecular biology from the University of Pennsylvania. On top of his responsibilities at Frazier, Naini also serves on the boards of directors of United Digestive, Northfield Medical, MedData, Alteon Health, 98point6, and most recently Aegis Living.
Firm: JMI Equity
Title: General Partner
Matt joined JMI in 2006 and focuses on JMI’s investments in software and healthcare IT businesses. In addition to supporting JMI’s current portfolio companies, he also helps to identify and assess potential investment opportunities in high-growth software companies. Matt has held numerous board positions at JMI portfolio companies during his tenure, and is currently a director of CiperHealth, Clio, Jvion, PointClickCare, and TimelyMD. Prior to joining JMI in 2006, Matt was an analyst in the technology investment banking group at Thomas Weisel Partners and a research associate at Thompson, Siegel & Walmsley. Matt is a CFA charterholder.
Firm: Spectrum Equity
Title: Managing Directors
Jeff Haywood and Steve LeSieur lead Spectrum Equity’s investment activity in healthcare, focusing on high growth Internet-enabled software and information services companies serving all parts of the healthcare market. Steve joined Spectrum in 2005 and currently serves on the following healthcare company boards including GoodRx (NASDAQ: GDRX) and Payer Compass and was previously involved with Definitive Healthcare, MedHOK (acquired by Hearst Health), HealthMEDX (acquired by NetSmart), Passport Health Communications (acquired by Experian) and QTC Management (acquired by Lockheed Martin). Jeff joined the firm in 2007 and currently serves on the following healthcare company boards including Definitive Healthcare, Payer Compass, RxVantage and Verisys. He also led Spectrum’s recent investment in PWNHealth and subsequent sale to Everlywell, where he continues as a board observer. Jeff was previously involved with GoodRx (NASDAQ: GDRX), MedHOK (acquired by Hearst Health), Net Health (acquired by The Carlyle Group), and Passport Health Communications (acquired by Experian).
“Spectrum Equity is committed to fostering long-standing partnerships with the founders and entrepreneurs building today’s market leading digital health companies. It is incredibly rewarding to support the efforts of management teams addressing the highly complex issues that exist, and are often unique, in healthcare. We believe the ongoing evolution of connected software, data and analytics will continue to have a massive impact on healthcare both in terms of increasing access to care and improving outcomes.” – Steve LeSieur & Jeff Haywood.
Firm: Insight Partners
Title: Managing Director
Nikhil Sachdev is a Managing Director at Insight Partners and focuses on leading venture and growth stage investments in high-growth software, Internet, healthcare, and FinTech companies. Nikhil has led investments in and serves on the boards of Mural, Apprentice.io, Viz.ai, TetraScience, inDriver and several other investments. Prior to joining Insight, Nikhil was a Partner at Altimeter Capital where he led investments in high growth private companies across the SaaS, DevOps, Internet, and gaming / social media categories. Nikhil holds an M.B.A. from Harvard Business School and a B.A. Honors from Stanford University.
“The healthcare industry has experienced rapid digital transformation across multiple sectors over the last few years and experienced a cataclysmic shift as a result of COVID-19. At Insight we are focused on partnering with transformational software companies across the entire healthcare ecosystem who are utilizing technology and digital solutions to create opportunity and drive change. From AI applications, to data analytics, to care coordination and collaboration software, we are privileged to work with world class founders and executive teams to support them as they scale up with capital, operating support, and strategic engagement at every level.”
Title: General Partner
Dr. David Bonita is a General Partner at OrbiMed, a leading healthcare investment firm with $13 billion in assets under management. Since joining OrbiMed in 2004, Dr. Bonita has led numerous transformative investments in innovative biopharmaceutical and medical device companies, including Loxo Oncology, Tricida, Cryterion Medical, and Therachon SAS, among others. These investments have contributed significantly to the financial returns enjoyed by OrbiMed’s clients. Prior to his time at OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. As a top mind in the field, he has published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School.
He received his A.B. degree magna cum laude in biological sciences from Harvard University and his joint Doctor of Medicine/Master of Business Administration degree from Columbia University, where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.
Firm: Norwest Venture Partners
Title: General Partner
Dr. Ryan Harris brings to Norwest Venture Partners more than thirty years of healthcare experience and twenty years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, and medical products. Ryan’s current investments include American Endovascular, Blue Cloud, Kyo (formerly Gateway Learning Group), Onsite Dental, Rivermend Health, and Target RWE. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Firm: Susquehanna Growth Equity
Title: Managing Director
Scott Feldman has been with Susquehanna since its inception. During his time with the firm he has led all of Susquehanna’s investments in the healthcare sector, including HMP, Evive, RLDatix, ProviderTrust, MMIT (sold to financial sponsor), and iContracts (sold to financial sponsor). Scott’s expertise traverses the entire healthcare sector and includes payer, provider, and pharma-facing companies.
Prior to joining Susquehanna, Scott was an investment banker serving telecom, technology, and internet companies. He began his career at Gabelli & Company. Scott graduated with a B.S. in Finance from the Wallace E. Carroll School of Management at Boston College.
Firm: Health Enterprise Partners
Title: Managing Partner
Ezra joined HEP in 2010, while completing his M.B.A. at Columbia Business School. Prior to joining the team, Ezra was a Senior Analyst at the Advisory Board Company (NASDAQ: ABCO), providing best practice consulting and research services to hospitals and health systems. After leaving the Advisory Board Company, Ezra served as a Senior Consultant in the healthcare practice of Booz Allen Hamilton focusing on engagements in the provider space.
Ezra is currently on the board of directors of CenterPointe Behavioral Health System, Jvion, Twistle, and Wildflower Health. He previously served on the board of directors AxiaMed (acquired by Bank of America), Applied Pathways (acquired by AIM Specialty Health, a division of Anthem, Inc) and InDemand Interpreting (acquired by Stratus Video/AMN Healthcare). He sits on the Harvard School of Public Health’s Health Policy and Management Executive Council. He is on the faculty of Columbia Business School. Ezra holds a B.A. cum laude from Washington University in St. Louis, and an M.B.A. from Columbia Business School.
Firm: JMI Equity
Sureel has been a part of the JMI team since 2010 and has a decade of experience partnering with growth software companies, particularly in the healthcare IT space. In addition to supporting JMI’s current portfolio companies, he also helps to identify and assess potential investment opportunities in high-growth software companies. He currently works with JMI portfolio companies Clio, Jvion, and PointClickCare, and played an active role with investments in CipherHealth, Yello, Healthx (acquired by Thoma Bravo), Adaptive Insights (acquired by Workday), and Capsule Tech (acquired by Qualcomm). Prior to joining JMI, Sureel was a business analyst at McKinsey & Company.
Firm: Pfizer Venture Investments
Title: Senior Managing Partner and Vice President, Worldwide Business Development
Barbara Dalton is currently a Senior Managing Partner at Pfizer Ventures and Vice President of Worldwide Business Development at Pfizer Inc. To date, she has spent over 30 years in the industry, gaining an unparalleled level of pharmaceutical venture expertise. Since joining Pfizer in 2007, Dr. Dalton has led Pfizer’s efforts to deploy capital to generate both financial returns and strategic opportunities. Under her leadership, Pfizer Ventures has invested more than $700 million in more than 90 portfolio company investments, building Pfizer Ventures into one of the leading corporate venture capital groups in the life sciences industry.
Following her Doctor of Philosophy degree in microbiology and immunology from the Medical College of Pennsylvania (now Drexel University School of Medicine), Dr. Dalton’s pharmaceutical career started in immunology at Smith Kline & French Research Laboratories. Later she transitioned to their venture capital group, S.R. One, Limited, where she spent a decade growing her expertise in venture investing. In 2000, Dr. Dalton also became a General Partner in the private venture fund, EuclidSR Partners, a position she held until joining Pfizer in 2007. In addition, she holds a Bachelor of Science degree in general science from Penn State.
Firm: River Cities Capital Funds
Patrick is a director at River Cities and has been with the firm for seven years. He is active in all aspects of the firm’s investment origination, deal structuring and portfolio management, and helps lead the firm’s HC Services strategy. He is currently on the Board of Directors of MindPath Care Centers and is also involved with Endodontic Practice Partners, UrgentTeam and Liquibase. Patrick led RCC’s thesis building and investment in MindPath, a market-leading outpatient psychiatry and therapy platform focused on the in-network commercial market. Patrick sourced the opportunity and helped build out the board and management team. The Company has more than doubled in size and developed an industry-leading reputation for high-quality clinical care and best-in-class clinician support.
Prior to joining RCC, Patrick worked for the CFO of a sponsor-backed company. Before that he worked at Ballast Point Ventures, where he worked on growth-stage investments in healthcare. Patrick started his career with Raymond James & Associates in their investment banking department. Patrick graduated with a B.S. in finance with honors from the University of Florida and an M.B.A. from the Fuqua School of Business at Duke University where he was in the Health Sector Management (HSM) program. Patrick serves on the boards of Communities in Schools for Wake County and the Council for Entrepreneurial Development (CED) for the Triangle region.
Firm: Novartis Venture Fund
Title: Global Head of the Novartis Venture Fund
Dr. Anja König is the Global Head of the Novartis Venture Fund, a global venture capital firm that has approximately $800 million under management as of 2020. She joined the team in 2006, initially serving as a managing director at NVF. Since then, she has overseen several successful exits for Novartis, including Switzerland-based biopharmaceutical company Covagen and UK-based Alzheimer’s disease drug developer Heptares via mergers and acquisitions, while Austria-based biopharmaceutical company Nabriva and South Korea-based biotech company Qurient were via initial public offerings.
Prior to NVF, Dr. König was a U.S.-based associate partner at management consultancy firm McKinsey for six years, where she worked with healthcare, pharmaceutical, and biotech firms on both sides of the Atlantic. Dr. König, who is currently active in the Swiss startup ecosystem and is a member of the board of the University of Zurich Life Sciences Fund, is a scientist by training. She holds a bachelor’s degree from the University of Oxford, a master’s degree from Ludwig Maximilian University of Munich, and a Doctor of Philosophy degree in physics from Cornell University.
Firm: Kaiser Permanente Ventures
Title: Senior Managing Director
Sam Brasch is a Senior Managing Director at Kaiser Permanente Ventures. He returned to KPV in 2016 to lead the corporate venture fund’s activities after serving as a venture partner at New Leaf Venture Partners and as a senior advisor to Health Catalyst. Brasch’s health care industry experience spans more than two decades. During his tenure at Kaiser Permanente Ventures from 2011 to 2014, he led the group’s investments in iRhythm Technologies, Health Catalyst, Nordic Consulting, and multiple other companies. Before that, Brasch was an executive-in-residence and vice president with Frazier Healthcare Ventures, a Seattle-based venture capital firm. At Frazier, he focused on venture and growth equity stage investments in the medical device and healthcare services sectors.
Brasch has also worked in multiple healthcare technology start-ups. Originally, he began his career as a management consultant with APM/CSC Healthcare, working primarily with hospital, physician group, and healthcare payor clients. He holds a B.A. degree in public policy from Stanford University and a M.B.A. degree in healthcare management from The Wharton School of the University of Pennsylvania.
Firm: Susquehanna Growth Equity
Title: Tech Investor
Sam Major joined Susquehanna in 2015. He primarily focuses on growth investments in healthcare, including those serving payers, providers, and pharmaceutical manufacturers. He played a large role in Susquehanna’s investments in iContracts, Evive, PerkSpot, RLDatix, and ProviderTrust and has also supported M&A activity at MMIT and HMP Global. Prior to joining Susquehanna, Sam graduated with a degree in history from Princeton University.
Copyright: The Top 25 Healthcare Investors of 2021 publication is copyrighted material, produced and published by GrowthCap, LLC. For information pertaining to content permissions, please refer to GrowthCap’s award usage regulations.
Disclaimer: The data provided in this publication is for informational purposes only and should not be construed as investment advice, endorsement, nor recommendation. GrowthCap believes the information in this publication to be accurate but does not verify its accuracy independently and does not warrant or guarantee that it is accurate or complete. GrowthCap has no obligation to provide any updates or changes to the information. No investment decisions should be made using this information.
Discover unique insights from leading executives and growth investors.
Sign up for our weekly newsletter.